Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of GB002 recombinant peptide in healthy Chinese adults
NCT06423261Phase 1Active, not recruiting
- Sponsor
- Zhejiang Echon Biopharm
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB002 (2 arms), sponsored by Zhejiang Echon Biopharm. Primary endpoint: Number of participants with adverse events. Started Aug 2023; status: active, not recruiting.
02
Drugs
GB002
Beyond the preview
Go deeper on NCT06423261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423261.